论文信息 - 4504 ORAL A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) – final results - 字舞流文

4504 ORAL A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) – final results

U. Harmenberg | C. Peschel | N. Vogelzang | B. Escudier | G. Fountzilas | S. Srinivas | S. Gillessen | J. Roigas | P. Flodgren | P. Mulder